Silver Book Fact

Treatment with zoledronic acid over a 3-year period reduced risk of vertebral fracture by around 70% and risk of hip fracture by 41%, and increased bone mineral density (BMD) by 5% to 6%.

Black D, Delmas P, Eastell R, et al. Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis. NEJM. 2007; 356(18): 1809-22. http://content.nejm.org/cgi/content/abstract/356/18/1809

Reference

Title
Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Publication
NEJM
Publication Date
2007
Authors
Black D, Delmas P, Eastell R, et al
Volume & Issue
Volume 356, Issue 18
Pages
1809-22
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Risedronate, a bisphosphonate, has been shown to reduce vertebral fractures by around 41%, hip fractures by 30%, and non-vertebral fractures by 39%.  
  • Teriparatide, or human recombinant PTH, has been shown to decrease vertebral fractures by 65% to 69%, and non-vertebral fragility fractures by around 53%.  
  • A meta-analysis of clinical trials found that calcium supplements reduced the risk of vertebral fractures by around 23%.  
  • A systematic review of osteoporosis therapies found good evidence that many are effective in preventing fractures, but concluded that the data are insufficient to determine if any one therapy is…  
  • The Study of Osteoporotic Fractures, which began over 20 years ago, found that bone mineral density (BMD) of the hip is one of the best predictors of fracture for women,…